Emtricitabine, Tenofovir Alafenamide, Bictegravir

• A clinical study of people with HIV‐1 who switch their treatment to a combination of doravirine and islatravir​​ Not authorised
  2022-502079-49-00 Phase III 4 countries Merck Sharp & Dohme LLC
• A clinical study of people with HIV-1 who have not taken antiretroviral therapy, one group will start treatment with a combination of doravi… Not authorised
  2022-502099-22-00 Phase III 6 countries Merck Sharp & Dohme LLC
• Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed Pending
  2024-511054-50-00 Phase II/III 6 countries Gilead Sciences Inc.
• Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy Recruiting
  2023-510022-33-00 Phase III 4 countries Gilead Sciences Inc.
• Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppres… Ended
  2024-514046-37-00 Phase III 3 countries Gilead Sciences Inc.
• Impact of Doravirine in Liver Steatosis and Fibrosis in PLWH. A pilot, proof of concept study (DORALI Study) Ended
  2023-504952-87-00 Phase IV 1 country Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocio…
• A clinical study of people with HIV-1 who have not taken antiretroviral therapy, one group will start treatment with a combination of doravi… Ended
  2022-502099-22-01 Phase III 3 countries Merck Sharp & Dohme LLC
• A study to evaluate the efficacy, safety, and tolerability of using an oral once-daily 2 drug regimen compared to an oral once-daily 3 drug … Ended
  2023-504993-40-00 Phase III 11 countries Viiv Healthcare UK Limited
• Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated Ended
  2024-512505-66-00 Phase II/III 5 countries Gilead Sciences Inc.
• Study of B/F/TAF in Participants Switching from CAB + RPV to B/F/TAF for HIV-1 Infection. Ended
  2023-506660-13-00 Phase IV 1 country Gilead Sciences Inc.
• Ph 3b, BIC/FTC/TAF to DTG/3TC FDC, 96 Week switch, efficacy, safety, and tolerability study in ART-experienced older adults living with HIV … Ended
  2022-503137-66-00 Phase III 8 countries Viiv Healthcare UK Limited
• Clinical Trial to Evaluate the Safety and Appropriateness of Switching from Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir A… Ended
  2024-511951-16-00 Phase IV 1 country Fundacion Seimc Gesida
• DTG/3TC vs BIC/FTC/TAF maintenance therapy in people living with HIV: an open-label randomized clinical trial Ended
  2024-515167-56-00 Phase III/IV 1 country Fundacion Seimc Gesida
• Dose Ranging, Switch Study of ISL and MK‑8507 Once-Weekly Ended
  2024-511041-19-00 Phase II 1 country Merck Sharp & Dohme LLC
• Virological and immunological assessment in HIV positive participants on 2DR versus 3DR in a prospective randomized controlled switch trial. Ended
  2024-515265-34-00 Phase IV 1 country Universitair Ziekenhuis Gent
• The Late Presenter Treatment Optimisation Study (LAPTOP) Ended
  2023-505167-36-00 Phase III 6 countries NEAT ID Foundation
• Study on Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Ended
  2024-515487-31-00 Phase IV 5 countries Stichting Radboud universitair medisch centrum

Showing 1–17 of 17 trials